Zongertinib demonstrates high objective response rates in previously treated advanced non-small cell lung cancer

Results from the phase Ib Beamion LUNG-1 trial found that zongertinib achieved an objective response rate of 66.7% in previously treated patients with advanced non-small cell lung cancer with HER2 mutations.